U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 3C15H17O3S.3Na.H2O
Molecular Weight 919.061
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EGUALEN SODIUM HYDRATE

SMILES

O.[Na+].[Na+].[Na+].CCC1=CC(=C2C=C(C=CC=C12)C(C)C)S([O-])(=O)=O.CCC3=CC(=C4C=C(C=CC=C34)C(C)C)S([O-])(=O)=O.CCC5=CC(=C6C=C(C=CC=C56)C(C)C)S([O-])(=O)=O

InChI

InChIKey=NLAZKIKOGLLKFO-UHFFFAOYSA-K
InChI=1S/3C15H18O3S.3Na.H2O/c3*1-4-11-9-15(19(16,17)18)14-8-12(10(2)3)6-5-7-13(11)14;;;;/h3*5-10H,4H2,1-3H3,(H,16,17,18);;;;1H2/q;;;3*+1;/p-3

HIDE SMILES / InChI
Egualen is an azulene derivative developed for the treatment of peptic ulcer and marketed in Japan under the tradename Azuloxa. The drug exerts its antiulcer activity by antagonizing TXA2 production.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AZULOXA

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Inhibitory effect of egualen sodium: a new stable derivative of azulene on histamine release from mast cell-like cells in the stomach.
2001
A ring expansion-annulation strategy for the synthesis of substituted azulenes. Preparation and Suzuki coupling reactions of 1-azulenyl triflates.
2001 Apr 5

Sample Use Guides

1 tablet (15 mg) or 0.6 g of 2.5% granules twice a day.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
EGUALEN SODIUM HYDRATE
JAN  
Common Name English
TRI(EGUALEN SODIUM) MONOHYDRATE
Common Name English
EGUALEN SODIUM HYDRATE [JAN]
Common Name English
Code System Code Type Description
FDA UNII
249501B040
Created by admin on Sat Dec 16 05:22:47 GMT 2023 , Edited by admin on Sat Dec 16 05:22:47 GMT 2023
PRIMARY
PUBCHEM
11954341
Created by admin on Sat Dec 16 05:22:47 GMT 2023 , Edited by admin on Sat Dec 16 05:22:47 GMT 2023
PRIMARY